Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma in patients with ch

[Guest guest]

Hepatology Research (OnlineEarly Articles).

doi:10.1111/j.1872-034X.2007.00316.x

Abstract

Original Article

Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma

in patients with chronic hepatitis C in whom viral eradication fails

Yukiko Miura,11Department of Gastroenterology, Kitasato University School of

Medicine and Dr Yukiko Miura, Department of Gastroenterology, Kitasato

University School of Medicine, 1-15-1 Kitasato, Sagamihara, Kanagawa 228-8555,

Japan. Email: dm04040j@... Akitaka Shibuya,11Department of

Gastroenterology, Kitasato University School of Medicine and Shigeru

Adachi,11Department of Gastroenterology, Kitasato University School of Medicine

and Atsuko Takeuchi,11Department of Gastroenterology, Kitasato University School

of Medicine and Takeshi Tsuchihashi,22Department of Gastroenterology, Fuchinobe

General Hospital, Sagamihara, Kanagawa, Japan Takahide Nakazawa11Department of

Gastroenterology, Kitasato University School of Medicine and and Katsunori

Saigenji11Department of Gastroenterology, Kitasato University School of Medicine

and 1Department of Gastroenterology, Kitasato University School of Medicine and

2Department of Gastroenterology, Fuchinobe General Hospital, Sagamihara,

Kanagawa, Japan

Dr Yukiko Miura, Department of Gastroenterology, Kitasato University School of

Medicine, 1-15-1 Kitasato, Sagamihara, Kanagawa 228-8555, Japan. Email:

dm04040j@...

Abstract

Aim: Recent studies have suggested that an occult hepatitis B virus (HBV)

infection negative for HBsAg but positive for HBV-DNA contributes to

hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C.

Some follow-up studies have suggested the clinical importance of occult HBV

infections in HCC development even after interferon (IFN) therapy, but a recent

study denies the significance of the impact of occult HBV infection. Focusing on

HCC development in patients in whom hepatitis C virus (HCV) eradication by

interferon (IFN) therapy had failed, we conducted this study in order to assess

the impact of occult HBV infections on HCC development in these patients.

Methods: We enrolled 141 patients with chronic hepatitis C (histological stage

F2 or F3) who were seropositive for HCV-RNA even after IFN therapy. Serum

HBV-DNA was assayed using the real-time polymerase chain reaction. During

follow-up, ultrasonography and/or computed tomography (CT) were performed at

least every 6 months to monitor HCC development.

Results: The cumulative incidence rates of HCC were 8.9%, 25.7% and 53.7% at 5

years, 10 years and 15 years, respectively, after IFN therapy. Multivariate

analysis indicated that low platelet counts (

_________________________________________________________________

Get the power of Windows + Web with the new Windows Live.

http://www.windowslive.com?ocid=TXT_TAGHM_Wave2_powerofwindows_012008

[Guest guest]

Hepatology Research (OnlineEarly Articles).

doi:10.1111/j.1872-034X.2007.00316.x

Abstract

Original Article

Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma

in patients with chronic hepatitis C in whom viral eradication fails

Yukiko Miura,11Department of Gastroenterology, Kitasato University School of

Medicine and Dr Yukiko Miura, Department of Gastroenterology, Kitasato

University School of Medicine, 1-15-1 Kitasato, Sagamihara, Kanagawa 228-8555,

Japan. Email: dm04040j@... Akitaka Shibuya,11Department of

Gastroenterology, Kitasato University School of Medicine and Shigeru

Adachi,11Department of Gastroenterology, Kitasato University School of Medicine

and Atsuko Takeuchi,11Department of Gastroenterology, Kitasato University School

of Medicine and Takeshi Tsuchihashi,22Department of Gastroenterology, Fuchinobe

General Hospital, Sagamihara, Kanagawa, Japan Takahide Nakazawa11Department of

Gastroenterology, Kitasato University School of Medicine and and Katsunori

Saigenji11Department of Gastroenterology, Kitasato University School of Medicine

and 1Department of Gastroenterology, Kitasato University School of Medicine and

2Department of Gastroenterology, Fuchinobe General Hospital, Sagamihara,

Kanagawa, Japan

Dr Yukiko Miura, Department of Gastroenterology, Kitasato University School of

Medicine, 1-15-1 Kitasato, Sagamihara, Kanagawa 228-8555, Japan. Email:

dm04040j@...

Abstract

Aim: Recent studies have suggested that an occult hepatitis B virus (HBV)

infection negative for HBsAg but positive for HBV-DNA contributes to

hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C.

Some follow-up studies have suggested the clinical importance of occult HBV

infections in HCC development even after interferon (IFN) therapy, but a recent

study denies the significance of the impact of occult HBV infection. Focusing on

HCC development in patients in whom hepatitis C virus (HCV) eradication by

interferon (IFN) therapy had failed, we conducted this study in order to assess

the impact of occult HBV infections on HCC development in these patients.

Methods: We enrolled 141 patients with chronic hepatitis C (histological stage

F2 or F3) who were seropositive for HCV-RNA even after IFN therapy. Serum

HBV-DNA was assayed using the real-time polymerase chain reaction. During

follow-up, ultrasonography and/or computed tomography (CT) were performed at

least every 6 months to monitor HCC development.

Results: The cumulative incidence rates of HCC were 8.9%, 25.7% and 53.7% at 5

years, 10 years and 15 years, respectively, after IFN therapy. Multivariate

analysis indicated that low platelet counts (

_________________________________________________________________

Get the power of Windows + Web with the new Windows Live.

http://www.windowslive.com?ocid=TXT_TAGHM_Wave2_powerofwindows_012008

[Guest guest]

Hepatology Research (OnlineEarly Articles).

doi:10.1111/j.1872-034X.2007.00316.x

Abstract

Original Article

Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma

in patients with chronic hepatitis C in whom viral eradication fails

Yukiko Miura,11Department of Gastroenterology, Kitasato University School of

Medicine and Dr Yukiko Miura, Department of Gastroenterology, Kitasato

University School of Medicine, 1-15-1 Kitasato, Sagamihara, Kanagawa 228-8555,

Japan. Email: dm04040j@... Akitaka Shibuya,11Department of

Gastroenterology, Kitasato University School of Medicine and Shigeru

Adachi,11Department of Gastroenterology, Kitasato University School of Medicine

and Atsuko Takeuchi,11Department of Gastroenterology, Kitasato University School

of Medicine and Takeshi Tsuchihashi,22Department of Gastroenterology, Fuchinobe

General Hospital, Sagamihara, Kanagawa, Japan Takahide Nakazawa11Department of

Gastroenterology, Kitasato University School of Medicine and and Katsunori

Saigenji11Department of Gastroenterology, Kitasato University School of Medicine

and 1Department of Gastroenterology, Kitasato University School of Medicine and

2Department of Gastroenterology, Fuchinobe General Hospital, Sagamihara,

Kanagawa, Japan

Dr Yukiko Miura, Department of Gastroenterology, Kitasato University School of

Medicine, 1-15-1 Kitasato, Sagamihara, Kanagawa 228-8555, Japan. Email:

dm04040j@...

Abstract

Aim: Recent studies have suggested that an occult hepatitis B virus (HBV)

infection negative for HBsAg but positive for HBV-DNA contributes to

hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C.

Some follow-up studies have suggested the clinical importance of occult HBV

infections in HCC development even after interferon (IFN) therapy, but a recent

study denies the significance of the impact of occult HBV infection. Focusing on

HCC development in patients in whom hepatitis C virus (HCV) eradication by

interferon (IFN) therapy had failed, we conducted this study in order to assess

the impact of occult HBV infections on HCC development in these patients.

Methods: We enrolled 141 patients with chronic hepatitis C (histological stage

F2 or F3) who were seropositive for HCV-RNA even after IFN therapy. Serum

HBV-DNA was assayed using the real-time polymerase chain reaction. During

follow-up, ultrasonography and/or computed tomography (CT) were performed at

least every 6 months to monitor HCC development.

Results: The cumulative incidence rates of HCC were 8.9%, 25.7% and 53.7% at 5

years, 10 years and 15 years, respectively, after IFN therapy. Multivariate

analysis indicated that low platelet counts (

_________________________________________________________________

Get the power of Windows + Web with the new Windows Live.

http://www.windowslive.com?ocid=TXT_TAGHM_Wave2_powerofwindows_012008

[Guest guest]

Hepatology Research (OnlineEarly Articles).

doi:10.1111/j.1872-034X.2007.00316.x

Abstract

Original Article

Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma

in patients with chronic hepatitis C in whom viral eradication fails

Yukiko Miura,11Department of Gastroenterology, Kitasato University School of

Medicine and Dr Yukiko Miura, Department of Gastroenterology, Kitasato

University School of Medicine, 1-15-1 Kitasato, Sagamihara, Kanagawa 228-8555,

Japan. Email: dm04040j@... Akitaka Shibuya,11Department of

Gastroenterology, Kitasato University School of Medicine and Shigeru

Adachi,11Department of Gastroenterology, Kitasato University School of Medicine

and Atsuko Takeuchi,11Department of Gastroenterology, Kitasato University School

of Medicine and Takeshi Tsuchihashi,22Department of Gastroenterology, Fuchinobe

General Hospital, Sagamihara, Kanagawa, Japan Takahide Nakazawa11Department of

Gastroenterology, Kitasato University School of Medicine and and Katsunori

Saigenji11Department of Gastroenterology, Kitasato University School of Medicine

and 1Department of Gastroenterology, Kitasato University School of Medicine and

2Department of Gastroenterology, Fuchinobe General Hospital, Sagamihara,

Kanagawa, Japan

Dr Yukiko Miura, Department of Gastroenterology, Kitasato University School of

Medicine, 1-15-1 Kitasato, Sagamihara, Kanagawa 228-8555, Japan. Email:

dm04040j@...

Abstract

Aim: Recent studies have suggested that an occult hepatitis B virus (HBV)

infection negative for HBsAg but positive for HBV-DNA contributes to

hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C.

Some follow-up studies have suggested the clinical importance of occult HBV

infections in HCC development even after interferon (IFN) therapy, but a recent

study denies the significance of the impact of occult HBV infection. Focusing on

HCC development in patients in whom hepatitis C virus (HCV) eradication by

interferon (IFN) therapy had failed, we conducted this study in order to assess

the impact of occult HBV infections on HCC development in these patients.

Methods: We enrolled 141 patients with chronic hepatitis C (histological stage

F2 or F3) who were seropositive for HCV-RNA even after IFN therapy. Serum

HBV-DNA was assayed using the real-time polymerase chain reaction. During

follow-up, ultrasonography and/or computed tomography (CT) were performed at

least every 6 months to monitor HCC development.

Results: The cumulative incidence rates of HCC were 8.9%, 25.7% and 53.7% at 5

years, 10 years and 15 years, respectively, after IFN therapy. Multivariate

analysis indicated that low platelet counts (

_________________________________________________________________

Get the power of Windows + Web with the new Windows Live.

http://www.windowslive.com?ocid=TXT_TAGHM_Wave2_powerofwindows_012008